NEW YORK (GenomeWeb News) – Synthetic biology startup Gen9 has completed the naming of its scientific advisory board. Three of its SAB members also are the founders of the Cambridge, Mass.-based company.
These members include George Church, a professor of genetics at Harvard Medical School, director of the Center for Computational Genetics, and co-founder of Knome; Drew Endy, an assistant professor of bioengineering at Stanford University, president of the BioBricks Foundation, and co-founder of the International Genetically Engineered Machines (iGEM) competition; and Joseph Jacobson, associate professor of the Massachusetts Institute of Technology and co-principal investigator of the Center for Bits and Atoms.
The other members of the SAB include University of Washington and Howard Hughes Medical Institute investigator David Baker; Stanford University graduate student in bioengineering and former member of Codon Devices Christopher Emig; Northwestern University Assistant Professor of Chemical and Biological Engineering Michael Jewett; and Sriram Kosuri, a staff scientist at the Wyss Institute for Biologically Inspired Engineering and Harvard Medical School and co-founder of the OpenWetWare bioscience data sharing website.
The Human Frontier Science Program Organization has awarded Stephen Quake the 2013 Nakasone Award for his work developing technologies in biophysics, biological automation, genome analysis, and personalized medicine.
Quake is a professor of bioengineering and a Howard Hughes Medical Institute investigator at Stanford University. He is also a co-founder of Helicos Biosciences and Fluidigm.
Arnold Levine has been appointed to GeneCentric's board of directors. Levine previously was president and CEO of Rockefeller University, and he was a professor of life sciences and chairman of the Molecular Biology Department at Princeton University from 1984 to 1998. During his career in research and administration, Levine has helped to discover the p53 tumor suppressor protein and he established the Simons Center for Systems Biology at the Institute for Advanced Study.
Personalized medicine and molecular diagnostics firm Nodality has appointed pharmaceutical, biotech, and venture capital executive Laura Brege to serve as company president and CEO. Brege formerly was executive VP and COO at Onyx Pharmaceuticals, and she was a general partner at Red Rock Capital Management. She also was senior VP and CFO at COR Therapeutics, CFO at Flextronics, and treasurer of The Cooper Companies.
Max Coppes has been named president of the BC Cancer Agency in Vancouver. Coppes formerly was senior VP of the Children's National Medical Centre, where he led the Center for Cancer and Blood Disorders. While serving as president at the agency, Coppes will continue to teach and practice medicine at the University of British Columbia and the BC Children's Hospital.
Louise Mawhinny has taken on the CFO post at Aratana Therapeutics. Mawhinny previously served as Helicos Biosciences' senior VP and CFO. She led the firm's initial public offering and left the company in 2008.
Dennis Lo has been awarded the Ernesto Illy Trieste Science Prize, which is given to scientists living and working in developing countries whose research has had a significant impact on sustainable development. Lo received the award for his work in the area of non-invasive prenatal diagnostics and his research demonstrating that it is possible to detect the fetal genome from maternal plasma.
Lo is the director of the Li Ka Shing Institute of Health Sciences and a professor of medicine at the Chinese University of Hong Kong.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.